Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte Stimulating Factor Injection (PEG-G-CSF) in Preventing Neutropenia After Chemotherapy

NCT06711523 is registered in ClinicalTrials.gov with Kexing Biopharm Co., Ltd. as lead sponsor.

NCT NCT06711523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06711523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte Stimulating Factor Injection (PEG-G-CSF) in Preventing Neutropenia After Chemotherapy
Lead sponsor
Kexing Biopharm Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 9, 2025
Completion date
June 30, 2026
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm female, neutropenia, chemotherapy-induced febrile